Parkin, a 465-amino acid residue E3 ubiquitin ligase, is a protein encoded by the PARK2 gene in human. Parkin performs important roles in ubiquitination, the process by which a molecule covalently binds to ubiquitin (Ub) and is aimed at the proteasome or lysosome for degradation. Parkin has two RING structural domains and an in-between-RING (IBR) region. RING1 constitutes the binding site for the E2 Ub-binding enzyme, while RING2 possesses the catalytic cysteine residue (Cys431) that disparate Ub from E2 and binds it transiently to E3 through a thioester bond.
Parkin also inhibits mitochondria-dependent and --independent apoptosis, thereby increasing cell survival. Mutations in the Parkin gene are also known to contribute to a familial form of Parkinson's disease referred to as autosomal recessive juvenile Parkinson's disease (AR-JP). In addition, Parkin has been reported to be essential for mitosis (autophagy of mitochondria).
Parkin in Parkinson’s Disease (PD)
PARK2 is a Parkin gene in which mutations in the Parkin protein can cause a form of autosomal recessive juvenile Parkinson's disease. This form of genetic mutation is thought to be one of the most common genetic causes of early-onset Parkinson's disease. In humans, 50% of inherited forms of Parkinson’s disease (PD) and 15% of sporadic juvenile-onset forms of Parkinson’s disease (PD) are associated with loss-of-function mutations in the parkin PARK2 gene.
Recombinant parkin has been reported to inhibit symptoms associated with Parkinson's disease; Cellivery has developed a recombinant cell-permeable Parkin protein (ICP-Parkin). Aaccording to some preclinical studies, ICP-Parkin integrates parkin into damaged dopaminergic cells. By doing so, Parkin protein (ICP-Parkin) can change the course of disease progression and affect motor symptoms.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Parkin
Parkin Pipelines
|
Generic Name
|
Brand Name/
Alternative Name
|
Indications
|
Manufacturer
|
Latest Stage
|
|
iCP-Parkin
|
CV-06
|
Parkinson's disease, Alzheimer's disease
|
Cellivery, Ildong
|
Pre-clinical
|
|
PRKN gene therapy
|
AAV vector therapy
|
Parkinson's disease
|
Passage Bio
|
Pre-clinical
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
